New Key Statistics Module, Z-Score and F-Score
NAS:TARS Key Ratios
| Market Cap $ M | 1,217.34 |
| Enterprise Value $ M | 998.27 |
| P/E(ttm) | -- |
| PE Ratio without NRI | -- |
| Forward PE Ratio | -- |
| Price/Book | 4.83 |
| Price/Sales | 13.84 |
| Price/Free Cash Flow | -- |
| Price/Owner Earnings | -- |
| Payout Ratio % | -- |
| Revenue (TTM) $ M | 83.00 |
| EPS (TTM) $ | -4.48 |
| Beneish M-Score | 19.27 |
| 10-y EBITDA Growth Rate % | -- |
| 5-y EBITDA Growth Rate % | -42.00 |
| y-y EBITDA Growth Rate % | -- |
| EV-to-EBIT | -6.85 |
| EV-to-EBITDA | -6.90 |
| PEG | -- |
| Shares Outstanding M | 38.04 |
| Net Margin (%) | -180.00 |
| Operating Margin % | -187.55 |
| Pre-tax Margin (%) | -180.00 |
| Quick Ratio | 6.99 |
| Current Ratio | 7.03 |
| ROA % (ttm) | -51.79 |
| ROE % (ttm) | -69.10 |
| ROIC % (ttm) | -1,591.79 |
| Dividend Yield % | -- |
| Altman Z-Score | 4.73 |
TARS Number of Guru Trades
TARS Volume of Guru Trades
Gurus Latest Trades with NAS:TARS
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
NAS:TARS is held by these investors
Total 1
Tarsus Pharmaceuticals Inc Insider Transactions
No Available Data
News about NAS:TARS
Total 0- 1
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers